INTELLIA THERAPEUTICS INC (NTLA) Stock Overview
NASDAQ:NTLA - US45826J1051 - Common Stock
NTLA Key Statistics, Chart & Performance
The current stock price of NTLA is 12.06 USD. In the past month the price increased by 5.24%. In the past year, price decreased by -38.84%.
NTLA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.07 | 375.50B | ||
| AMGN | AMGEN INC | 13.01 | 152.70B | ||
| GILD | GILEAD SCIENCES INC | 14.86 | 142.76B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.38 | 101.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.56 | 60.77B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.25B | ||
| ARGX | ARGENX SE - ADR | 80.99 | 45.95B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.99 | 40.63B | ||
| INSM | INSMED INC | N/A | 30.67B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.03B | ||
| NTRA | NATERA INC | N/A | 23.06B | ||
| BIIB | BIOGEN INC | 8.79 | 20.62B |
Related stock screener links
About NTLA
Company Profile
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. The company is headquartered in Cambridge, Massachusetts and currently employs 403 full-time employees. The company went IPO on 2016-05-06. CRISPR is a gene editing technology which is also sometimes referred to as CRISPR/Cas or CRISPR/Cas9 when referring to the use of CRISPR technology with the Cas9 enzyme. Its in vivo product candidates address genetic diseases by deploying its technologies, including CRISPR/Cas9 delivered by LNPs, as the therapy for diseases with high unmet need. Its lead in vivo product candidates, nexiguran ziclumeran (nex-z or NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE), are the first CRISPR-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. For its ex vivo product candidates, it applies its technologies to create engineered cell therapies to address immuno-oncology and autoimmune diseases.
Company Info
INTELLIA THERAPEUTICS INC
40 Erie St Ste 130
Cambridge MASSACHUSETTS 02139 US
CEO: John M. Leonard
Employees: 403
Phone: 18572856200
INTELLIA THERAPEUTICS INC / NTLA FAQ
What is the stock price of INTELLIA THERAPEUTICS INC today?
The current stock price of NTLA is 12.06 USD. The price increased by 3.79% in the last trading session.
What is the ticker symbol for INTELLIA THERAPEUTICS INC stock?
The exchange symbol of INTELLIA THERAPEUTICS INC is NTLA and it is listed on the Nasdaq exchange.
On which exchange is NTLA stock listed?
NTLA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for INTELLIA THERAPEUTICS INC stock?
33 analysts have analysed NTLA and the average price target is 33.84 USD. This implies a price increase of 180.58% is expected in the next year compared to the current price of 12.06. Check the INTELLIA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is INTELLIA THERAPEUTICS INC worth?
INTELLIA THERAPEUTICS INC (NTLA) has a market capitalization of 1.29B USD. This makes NTLA a Small Cap stock.
How many employees does INTELLIA THERAPEUTICS INC have?
INTELLIA THERAPEUTICS INC (NTLA) currently has 403 employees.
What are the support and resistance levels for INTELLIA THERAPEUTICS INC (NTLA) stock?
INTELLIA THERAPEUTICS INC (NTLA) has a support level at 12.03 and a resistance level at 13.6. Check the full technical report for a detailed analysis of NTLA support and resistance levels.
Is INTELLIA THERAPEUTICS INC (NTLA) expected to grow?
The Revenue of INTELLIA THERAPEUTICS INC (NTLA) is expected to grow by 14.7% in the next year. Check the estimates tab for more information on the NTLA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy INTELLIA THERAPEUTICS INC (NTLA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NTLA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NTLA, evaluating the profitability, health, valuation and growth aspects
- INTELLIA THERAPEUTICS INC (NTLA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INTELLIA THERAPEUTICS INC (NTLA) Sales and EPS estimates to see what analysts future expectations are.
- INTELLIA THERAPEUTICS INC (NTLA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INTELLIA THERAPEUTICS INC (NTLA) Insider and Institutional Ownership to learn about the owners and their transactions.
- INTELLIA THERAPEUTICS INC (NTLA) Stock Chart to make your own analysis
- INTELLIA THERAPEUTICS INC (NTLA) Latest news and press-releases to stay up to date.
Does INTELLIA THERAPEUTICS INC (NTLA) stock pay dividends?
NTLA does not pay a dividend.
When does INTELLIA THERAPEUTICS INC (NTLA) report earnings?
INTELLIA THERAPEUTICS INC (NTLA) will report earnings on 2025-11-05, before the market open.
What is the Price/Earnings (PE) ratio of INTELLIA THERAPEUTICS INC (NTLA)?
INTELLIA THERAPEUTICS INC (NTLA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.69).
What is the Short Interest ratio of INTELLIA THERAPEUTICS INC (NTLA) stock?
The outstanding short interest for INTELLIA THERAPEUTICS INC (NTLA) is 27.19% of its float. Check the ownership tab for more information on the NTLA short interest.
NTLA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to NTLA. When comparing the yearly performance of all stocks, NTLA turns out to be only a medium performer in the overall market: it outperformed 48.23% of all stocks.
NTLA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NTLA. While NTLA seems to be doing ok healthwise, there are quite some concerns on its profitability.
NTLA Financial Highlights
Over the last trailing twelve months NTLA reported a non-GAAP Earnings per Share(EPS) of -4.69. The EPS increased by 14.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.42% | ||
| ROE | -67.14% | ||
| Debt/Equity | 0 |
NTLA Forecast & Estimates
33 analysts have analysed NTLA and the average price target is 33.84 USD. This implies a price increase of 180.58% is expected in the next year compared to the current price of 12.06.
For the next year, analysts expect an EPS growth of 20.59% and a revenue growth 14.7% for NTLA